Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.0
3.4
Journals
Life
Special Issues
Skin Aging and Dermatosis
share announcement

Skin Aging and Dermatosis

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Medical Research".

Deadline for manuscript submissions: closed (26 February 2026) | Viewed by 3662

Special Issue Editors

Prof. Dr. Edwin Lephart

E-Mail Website
Guest Editor
Department of Cell Biology/Physiology and The Neuroscience Center, College of Life Sciences, Brigham Young University, Provo, UT 84602, USA
Interests: dermatology; menopause; estrogen hormone actions; natural products (phytochemical); factors that influence skin aging
Special Issues, Collections and Topics in MDPI journals
Dr. Zoe D. Draelos

E-Mail Website
Guest Editor
Dermatology Consulting Services, PLLC, High Point, NC 27262, USA
Interests: dermatology; skin aging; dermatosis
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue, “Skin Aging and Dermatosis”, will explore a variety of topics in the field of dermatology.

Skin aging is natural, such as chronological and photo-aging, is largely unavoidable, but lifestyle factors can slow down or delay aging, extending longevity and improving dermal wellbeing. The most dominant hormonal influence on skin aging is estrogen (17β-estradiol); its gradual decline and eventual loss during menopause affects almost all organ systems, having a profound and overall negative impact of the quality of life of women.

Menopause hormone therapy (MHT) can reverse several skin aging parameters. However, the fear, confusion, and hesitancy of physicians to prescribe MHT to women even with menopausal symptoms (vasomotor, hot flashes, etc.) has led to a scientific re-evaluation of the benefits and risks of MHT, causing a resurgence of topical estrogen applications to combat skin aging and estrogen-deficient skin during menopause. Moreover, there are other active ingredients, such as vitamins C and E, hyaluronic acid, retinoids, niacinamide, and naturally derived products (phytochemicals), that are highly effective in combating skin aging.

Dermatosis is associated with skin aging, the most common conditions of which include dermatoyositis, erythema nodosum, pemphigus vulgaris, psoriasis, sclerodema, Sweet syndrome, systemic lupus erythematosus, and vitiligo. Dermatosis can be caused by a variety of factors, including infections, irritants, allergies, genetic factors, autoimmune issues, and even certain medical conditions or medications.

This Special Issue will present the current status of research and potential future innovations regarding skin aging and dermatosis, serving as a valuable resource for dermatologists and clinical, corporate, and personal care professionals.

You may choose our Joint Special Issue in Cosmetics.

Prof. Dr. Edwin Lephart
Dr. Zoe D. Draelos
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • skin aging
  • chronological dermal aging
  • photo-aging
  • hormone therapy
  • menopause
  • estrogen-deficient skin
  • dermatosis
  • skin conditions

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review, Other

10 pages, 1209 KB  
Article
The Combined Benefits of Definisse™ Revitalise Threads and Definisse [KP1]® Redensifying Cream Treatments: A 19-Patient Case Series
by Adriano Santorelli, Alberto Mentone, Federico Maria D’Alessio, Stefano Uderzo, Martina Manni and Vincent Wong
Life 2026, 16(3), 465; https://doi.org/10.3390/life16030465 - 12 Mar 2026
Viewed by 431
Abstract
Peptides, particularly SA1-III decapeptide, play a key role in maintaining skin structure by inhibiting collagen degradation. The aim of this analysis was to investigate the combined effects of Definisse™ Revitalise Threads and Definisse [KP1]® Redensifying Cream containing SA1-III for facial rejuvenation. Patients [...] Read more.
Peptides, particularly SA1-III decapeptide, play a key role in maintaining skin structure by inhibiting collagen degradation. The aim of this analysis was to investigate the combined effects of Definisse™ Revitalise Threads and Definisse [KP1]® Redensifying Cream containing SA1-III for facial rejuvenation. Patients receiving Definisse™ Revitalise Threads were offered Definisse™ Redensifying Cream for one month. Outcomes—including efficacy, safety, and patient satisfaction—were assessed over six months using 3D imaging, clinical evaluation, and the FACE-Q™ questionnaire. Due to the sample size, data were summarised descriptively, with group comparisons using exact Mann–Whitney U tests and paired analyses using the Wilcoxon signed-rank test (p < 0.05). Nineteen individuals underwent treatment with Definisse™ Revitalise Threads (17 females and 2 males, aged 38–72 years); 10 patients used additional Definisse [KP1]® Redensifying Cream while 9 did not. All patients reported significant improvements in skin satisfaction, cheek fullness, and perceived aging, based in FACE-QTM scores before and after treatment. Thread treatment visibly improved facial appearance, but the addition of the peptide-containing cream further enhanced skin quality. Indeed, greater improvements in skin satisfaction were reported by individuals using vs. not using Definisse [KP1]® Redensifying Cream. No adverse events were reported, and the FACE-QTM Adverse Effects scale indicated only mild, transient effects. In this preliminary series with a six-month follow-up, the combination of Definisse Revitalise Threads and Definisse® Redensifying Cream was well-tolerated and showed potential for enhancing facial rejuvenation. These preliminary findings suggest that peptide-based cosmeceuticals may complement aesthetic procedures and support skin health. These preliminary results will be used to generate hypotheses for larger studies with longer follow-up, which are needed to confirm these effects. Full article
(This article belongs to the Special Issue Skin Aging and Dermatosis)
►▼ Show Figures

Figure 1

Review

Jump to: Research, Other

16 pages, 1379 KB  
Review
Pharmacomicrobiomics in Psoriasis: Microbiome–Drug Interactions Across Systemic Treatments
by Umberto Santaniello, Luca Mastorino, Valentina Pala, Francois Rosset, Orsola Crespi, Pietro Quaglino and Simone Ribero
Life 2026, 16(3), 415; https://doi.org/10.3390/life16030415 - 4 Mar 2026
Viewed by 849
Abstract
Psoriasis is a chronic immune-mediated skin disease with highly variable responses to systemic therapies. Emerging evidence highlights the microbiome as a potential modulator of drug efficacy and toxicity. Gut bacteria can enzymatically metabolize drugs, such as methotrexate, altering bioavailability and therapeutic outcomes, while [...] Read more.
Psoriasis is a chronic immune-mediated skin disease with highly variable responses to systemic therapies. Emerging evidence highlights the microbiome as a potential modulator of drug efficacy and toxicity. Gut bacteria can enzymatically metabolize drugs, such as methotrexate, altering bioavailability and therapeutic outcomes, while microbial metabolites—including short-chain fatty acids, branched-chain amino acids, and tryptophan derivatives—shape host immunity and barrier integrity, influencing drug action. Baseline microbial signatures have been linked to treatment response, potentially predicting anti-TNF or IL-17 inhibitor efficacy. Systemic therapies themselves reshape microbial communities: IL-17 blockade induces broad shifts in gut and skin microbiota, whereas cyclosporine and anti-TNF agents exert subtler effects. Small molecules such as apremilast and fumarates may reduce fungal overgrowth and influence microbial composition, whereas data on JAK/TYK2 inhibitors remain limited. Notably, current evidence exhibits a literature bias toward the gut microbiota, while the roles of the oral and skin axes remain understudied. Adjunctive microbiome-directed interventions, including probiotics and fecal microbiota transplantation, have demonstrated potential to enhance treatment outcomes by promoting anti-inflammatory taxa and restoring barrier function. Despite these promising findings, current evidence is heterogeneous, often limited by small sample sizes, short follow-up, and variable methodology. Integrating pharmacomicrobiomics data with clinical, genetic, and multi-omics profiling could enable precision medicine approaches in psoriasis, allowing therapy selection tailored to individual microbial and metabolic signatures. Future research should focus on longitudinal, multicenter studies to identify actionable microbial biomarkers, clarify mechanistic interactions between drugs, microbes, and host immunity, and evaluate microbiome-targeted adjuncts in randomized trials. Understanding the bidirectional crosstalk between systemic therapies and the microbiome may transform psoriasis management, improving efficacy, reducing adverse events, and enabling durable, personalized responses. Full article
(This article belongs to the Special Issue Skin Aging and Dermatosis)
►▼ Show Figures

Figure 1

Other

Jump to: Research, Review

14 pages, 1073 KB  
Perspective
Overview of Aging, Skin Health, Estrogen, Menopause and HRT
by Edwin D. Lephart and Zoe D. Draelos
Life 2026, 16(3), 401; https://doi.org/10.3390/life16030401 - 2 Mar 2026
Cited by 1 | Viewed by 1914
Abstract
While skin aging is inevitable, healthy habits, sun protection, skincare, and medical interventions can slow visible skin changes; estrogen is also crucial. In 2002, the Women’s Health Initiative (WHI) results contributed to the subsequent trend toward fear and avoidance of hormone replacement therapy [...] Read more.
While skin aging is inevitable, healthy habits, sun protection, skincare, and medical interventions can slow visible skin changes; estrogen is also crucial. In 2002, the Women’s Health Initiative (WHI) results contributed to the subsequent trend toward fear and avoidance of hormone replacement therapy (HRT). Since 2002, the WHI results have been re-evaluated and caused the US FDA to announce “the removal of the misleading FDA warnings on HRT”, stating that “estrogen is a key hormone for women’s health where every single part of a woman’s body depends on estrogen to operate at its best—including the brain, bones, heart, and muscles”. This overview explores this transformation of scientific information/perspective on HRT via (a) aging and skin health; (b) the importance and changes in estrogen in women with a focus on dermal parameters; (c) provides a brief review of the WHI result, impact, and current status of this report; (d) explores the “timing hypothesis” for HRT interventions; and (e) proposes that HRT might be considered not only for symptomatic women but also for esthetic treatment in perimenopause and menopause patients. The latest reviews support a recent large-scale systematic review and meta-analysis on skin parameters, which suggests that HRT may have a place in esthetic treatment. However, beyond esthetic benefits, the positive implications of HRT on several other health parameters in women during aging are briefly presented. Of course, hormonal and numerous other treatments require a review of the risks/benefits and their discussion among the patient and medical professionals to determine the most effective interventions for treating hormone-related skin changes, but this shift in perspective warrants further investigation and validation. Full article
(This article belongs to the Special Issue Skin Aging and Dermatosis)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop